|Michael T. Heffernan|
Mr. Heffernan has more than 25 years of experience in the pharmaceutical and related healthcare industries. He is currently the founder, president and CEO of Collegium Pharmaceutical, Inc. Prior to Collegium, he was the founder, president and CEO of Onset Dermatologics, a dermatology focused company that was spun out of Collegium to create PreCision Dermatology, which was acquired by Valeant (2014). Mr. Heffernan held prior positions as co-founder, president and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that was acquired by PhyMatrix Corp. and later served as president and CEO of PhyMatrix. Mr. Heffernan began his career at Eli Lilly and Company and served in numerous sales and marketing roles. Mr. Heffernan is currently the chairman of the board for Veloxis Pharmaceuticals. Mr. Heffernan earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.